Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Julio RosenstockRifat EmralLeobardo Sauque-ReynaViswanathan MohanCarlos TrescolíSaud Al SifriNebojsa LalicAgustina AlvarezPascaline PicardMireille BonnemaireNacima DemilRory J McCrimmonnull nullPublished in: Diabetes care (2021)
Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy. VIDEO 1: diacare;dc21-0393v4/F1F1f1Infographic available at https://care.diabetesjournals.org/content/dc21-0393-infographic.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- randomized controlled trial
- weight loss
- physical activity
- insulin resistance
- dendritic cells
- healthcare
- palliative care
- body mass index
- study protocol
- systematic review
- clinical trial
- metabolic syndrome
- chronic pain
- replacement therapy
- mesenchymal stem cells
- cell therapy
- weight gain
- combination therapy